Advertisement
In The Literature
Br J Haematol.

Elotuzumab in combination with thalidomide and low-dose dexamethasone

Leukemia

Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents

Bone Marrow Transplant

Autologous stem cell transplant for multiple myeloma patients 70 years or older

Ann Hematol.

Observational study of multiple myeloma in Latin America

J Clin Oncol

Association Between Treatment Facility Volume and Mortality of Patients With Multiple Myeloma

Br J Haematol

Multiple myeloma and family history of lymphohaematopoietic cancers: Results from the International Multiple Myeloma Consortium

Biol Blood Marrow Transplant

Post-Transplant Outcomes in High-Risk Compared With Non-High-Risk Multiple Myeloma: A CIBMTR Analysis

Cancer

Impact of marital status, insurance status, income, and race/ethnicity on the survival of younger patients diagnosed with multiple myeloma in the United States

Int J Hematol

Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?

N Engl J Med

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

Clin Lymphoma Myeloma Leuk

Clonal Evolution in Multiple Myeloma

Oncology (Williston Park)

COUNTERPOINT: Routine Use of Autologous Stem Cell Transplantation in Multiple Myeloma

Oncology (Williston Park)

POINT: Routine Use of Autologous Stem Cell Transplantation in Multiple Myeloma

Nat Rev Clin Oncol

Genomic complexity of multiple myeloma and its clinical implications

Hematol Oncol

Risk of stroke in patients with newly diagnosed multiple myeloma: a retrospective cohort study

The Lancet Oncology

Lenalidomide Plus Dexamethasone Versus Observation in Patients With High-Risk Smouldering Multiple Myeloma (QuiRedex): Long-Term Follow-Up of a Randomised, Controlled, Phase 3 Trial

J Manag Care Spec Pharm

Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model

Oncologist

Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD

Biol Blood Marrow Transplant

Post-Transplant Outcomes in High-Risk Compared to Non-High Risk Multiple Myeloma

The Lancet Oncology

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

Expert Review of Hematology

Real-World Treatment Patterns and Associated Progression-Free Survival in Relapsed/Refractory Multiple Myeloma Among US Community Oncology Practices

Leukemia & Lymphoma

Asia-Pacific Hematology Consortium Report on Approach to Multiple Myeloma. Survey Results From the 6th International Hematologic Malignancies Conference: Bridging the Gap 2015, Beijing, China

Cancer

Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin With Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma

American Journal of Hematology

Multiple Myeloma: 2016 Update on Diagnosis, Risk Stratification, and Management

Journal of Clinical Oncology

Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial

Lancet Haematology

The Effect of Salvage Autologous Stem-Cell Transplantation on Overall Survival in Patients With Relapsed Multiple Myeloma (Final Results From BSBMT/UKMF Myeloma X Relapse [Intensive]): A Randomised, Open-Label, Phase 3 Trial

Bone Marrow Transplant

Bendamustine, Etoposide and Dexamethasone to Mobilize Peripheral Blood Hematopoietic Stem Cells for Autologous Transplantation in Patients with Multiple Myeloma

Cancer

Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin With Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma

Leukemia

Early Relapse Following Initial Therapy for Multiple Myeloma Predicts Poor Outcomes in the era of Novel Agents

Blood

Clinical Efficacy of Daratumumab Monotherapy in Patients With Heavily Pretreated Relapsed or Refractory Multiple Myeloma

Blood

Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone in STRATUSTM (MM-010): A Phase 3b Study in Refractory Multiple Myeloma

Leukemia & Lymphoma

A Systematic Literature Review and Network Meta-Analysis of Treatments for Patients With Untreated Multiple Myeloma Not Eligible for Stem Cell Transplantation

Leukemia

Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma in Europe: Trends and Outcomes Over 25 Years. A Study by the EBMT CMWP

Blood

Minimal Residual Disease Monitoring and Immune Profiling Using Second Generation Flow Cytometry in Elderly Multiple Myeloma

Leukemia

Bence Jones Proteinuria in Smoldering Multiple Myeloma as a Predictor Marker of Progression to Symptomatic Multiple Myeloma

The New England Journal of Medicine

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

JNCCN—Journal of the National Comprehensive Cancer Network

NCCN Guidelines Insights: Multiple Myeloma

Current Opinion in Pharmacology

New Approaches to Targeting the Bone Marrow Microenvironment in Multiple Myeloma

European Journal of Haematology

Outcome of Allogeneic Transplantation in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Long-Term Follow-Up in a Single Institution

Clinical Lymphoma, Myeloma & Leukemia

VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma

Clinical Chemistry and Laboratory Medicine

Monitoring Multiple Myeloma Patients Treated With Daratumumab: Teasing Out Monoclonal Antibody Interference

Cancer Genomics & Proteomics

Identification of Prognostically Relevant Chromosomal Abnormalities in Routine Diagnostics of Multiple Myeloma Using Genomic Profiling

Circulation

Cardiovascular Complications of Novel Multiple Myeloma Treatments

Bone

The Effects of Proteasome Inhibitors on Bone Remodeling in Multiple Myeloma

Leukemia & Lymphoma

Outcomes and Management of Lenalidomide-Associated Rash in Patients With Multiple Myeloma

American Journal of Hematology

Central Nervous System Involvement by Multiple Myeloma: A Multi-institutional Retrospective Study of 172 Patients in Daily Clinical Practice

Journal of Oncology Pharmacy Practice

Multiple Myeloma: Updates for Pharmacists in the Treatment of Relapsed and Refractory Disease

Leukemia & Lymphoma

Connect MM® – The Multiple Myeloma Disease Registry: Incidence of Second Primary Malignancies in Patients Treated With Lenalidomide

Lancet

Daratumumab Monotherapy in Patients With Treatment-Refractory Multiple Myeloma (SIRIUS): An Open-Label, Randomised, Phase 2 Trial

British Journal of Haematology

Chimeric Antigen Receptor (CAR) Therapy for Multiple Myeloma

Cellular and Molecular Life Sciences

Immune Responses in Multiple Myeloma: Role of the Natural Immune Surveillance and Potential of Immunotherapies

Leukemia

Targeting Vasculogenesis to Prevent Progression in Multiple Myeloma

Bone Marrow Transplantation

Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: Efficacy and cost analysis study

Bone Marrow Transplantation

Allogeneic stem cell transplantation for multiple myeloma: Is there a future?

Blood

Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma

Leukemia and Lymphoma

Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting)

Blood Cancer Journal

Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial

Cancer

Impact of Access to NCI- and NCCN-Designated Cancer Centers on Outcomes for Multiple Myeloma Patients: A SEER Registry Analysis

British Journal of Haematology

Efficacy and Safety of Salvage Therapy Using Carfilzomib for Relapsed or Refractory Multiple Myeloma Patients: A Multicentre Retrospective Observational Study

Journal of the National Cancer Institute

Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review

Acta Haematologica

The Shreveport Myeloma Experience: Survival, Risk Factors and Other Malignancies in the Age of Stem Cell Transplantation

Expert Review of Anticancer Therapy

Oral Ixazomib Maintenance Therapy in Multiple Myeloma



click me